References

Cancer statistics, 2005

10.3322/canjclin.55.1.10 · 2005 · External reference

Therapy for older AML patients: the role of novel agents and allogeneic stem cell transplant

10.6004/jnccn.2008.0077 · 2008 · External reference

Non-transplant therapy for older patients with acute myeloid leukemia

10.6004/jnccn.2006.0006 · 2006 · External reference

Improvements in survival of adults diagnoses with acute myeloblastic leukemia in the early 21st center

10.3324/haematol.12304 · 2008 · External reference

Age and acute myeloid leukemia

10.1182/blood-2005-09-3724 · 2006 · External reference

De novo and secondary acute myeloid leukemia in patients over the age of 65: a review of fifty-six successive and unselected cases from a general hospital

10.3109/10428199909145732 · 1999 · External reference

Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: A study by the German Acute Myeloid Leukemia Cooperative Group

10.1200/jco.2007.15.4245 · 2009 · External reference

Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60years: results for AMLSG trial AML HD98-B

10.1182/blood-2006-04-014324 · 2006 · External reference

Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkable distinct responses to standard chemotherapy. A Southwest Oncology Group study

10.1182/blood.v89.9.3323 · 1997 · External reference

Results of intensive chemotherapy in 998 patients aged 65years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome — predictive models for outcome

10.1002/cncr.21723 · 2005 · External reference

Treatment of older patients with acute myeloid leukemia-new agents

10.1053/j.seminhematol.2006.01.003 · 2006 · External reference

Clinical trials in older adults with cancer: past and future

2007 · External reference

Treatment of elderly cancer patients with chemotherapy

10.1080/07357900500202770 · 2005 · External reference

A phase I and pharmacodynamic study of sequential topotecan and etoposide in patients with relapsed or refractory acute myelogenous and lymphoblastic leukemia

10.1016/s0145-2126(02)00079-6 · 2003 · External reference

A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia

10.1158/1078-0432.ccr-04-0097 · 2004 · External reference

Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia

10.1080/10428190701573208 · 2007 · External reference

(SB-715992) in relapsed/refractory acute leukemia [abstract]

2008 · External reference

Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia

10.1182/blood-2007-06-095844 · 2007 · External reference

Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia

10.1200/jco.2003.04.036 · 2003 · External reference

Non-parametric estimation from incomplete observations

10.2307/2281868 · 1958 · External reference

Regression models and life-tables (with discussion)

10.1111/j.2517-6161.1972.tb00899.x · 1972 · External reference

10.1214/ss/1009213286

10.1214/ss/1009213286 · External reference

Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia

10.1200/jco.2009.23.9178 · 2010 · External reference

Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors

10.1200/jco.2009.23.3130 · 2010 · External reference

Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia

10.1200/jco.2009.24.2008 · 2010 · External reference

Intensive consolidation versus oral maintenance therapy in patients 61years of older with acute myeloid leukemia in first remission: results of second randomization of the AML HD98-B treatment Trial

10.1038/sj.leu.2404122 · 2006 · External reference

Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML 11 trial

10.1182/blood.v98.5.1302 · 2001 · External reference

Never too old? Age should not be a barrier to enrollment in cancer clinical trials

10.1634/theoncologist.10-3-198 · 2005 · External reference

Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study

10.1016/j.critrevonc.2008.11.002 · 2009 · External reference

Safety and outcome of definitive chemoradiatherapy in elderly patients with oesophageal cancer

10.1038/sj.bjc.6604749 · 2008 · External reference

Phase II study of docetaxel and carboplatin in elderly patients with advanced non-small cell lung cancer

10.1097/jto.0b013e31819846e4 · 2009 · External reference

Amongst eligible patients, age and comorbidity do not predict for dose-limiting toxicity from phase I chemotherapy

10.1007/s00280-009-1084-8 · 2010 · External reference

Prognostic index for adult patients with acute myeloid leukemia in first relapse

10.1200/jco.2005.06.027 · 2005 · External reference

Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia

2004 · External reference

Aggressive salvage treatment is not appropriate for the majority of elderly patients with acute myeloid leukemia relapsing after first complete remission

2001 · External reference

The outcomes and costs of acute myeloid leukemia among the elderly

10.1001/archinte.162.14.1597 · 2002 · External reference